Advances in ART Pharmacology: Drug Delivery Systems and the Pipeline

doi:10.1017/9781108859486.004

Chapter 3 - Advances in ART Pharmacology: Drug Delivery Systems and the Pipeline

Published online by Cambridge University Press: 02 March 2020

Edited by

Denny Sakkas and

Alice D. Domar: Affiliation:
Boston IVF, Waltham, MA
Denny Sakkas: Affiliation:
Boston IVF, Waltham, MA
Thomas L. Toth: Affiliation:
Boston IVF, Waltham, MA

Book contents

Get access

Summary

Since the very early years (1969–1978) of human IVF, Patrick Steptoe and Robert Edwards were utilizing a range of pharmaceutical agents for ovarian stimulation, ovulation induction, and luteal phase support (e.g., urinary gonadotrophins, chorionic gonadotrophin, clomiphene citrate, progesterone). However, in spite of their efforts with these agents, their breakthrough pregnancy following ovarian stimulation was sadly an ectopic.

Type: Chapter
Information: Patient-Centered Assisted Reproduction
How to Integrate Exceptional Care with Cutting-Edge Technology
, pp. 23 - 38

DOI: https://doi.org/10.1017/9781108859486.004 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Elder, K, Johnson, MH. The Oldham Notebooks: An Analysis of the Development of IVF 1969–1978. I. Introduction, Materials and Methods. Reprod Biomed Soc Online. 2015; 1(1): 3–8.Google Scholar

Elder, K, Johnson, MH. The Oldham Notebooks: An Analysis of the Development of IVF 1969–1978. II. The Treatment Cycles and Their Outcomes. Reprod Biomed Soc Online. 2015; 1(1): 9–18.Google Scholar

Steptoe, PC, Edwards, RG. Reimplantation of a Human Embryo with Subsequent Tubal Pregnancy. Lancet. 1976; 1(7965): 880–2.Google Scholar

Steptoe, PC, Edwards, RG. Birth After the Reimplantation of a Human Embryo. Lancet. 1978; 2(8085): 366.CrossRef Google Scholar PubMed

Cohen, J, Trounson, A, Dawson, K, et al. The Early Days of IVF Outside the UK. Hum Reprod Update. 2005; 11(5): 439–59.Google Scholar

Edwards, RG, Lobo, R, Bouchard, P. Time to Revolutionize Ovarian Stimulation. Hum Reprod. 1996; 11(5): 917–19.Google Scholar

Alper, MM, Fauser, BC Ovarian Stimulation Protocols for IVF: Is More Better Than Less? Reprod Biomed Online. 2017; 34(4): 345–53.Google Scholar

Drakopoulos, P, Blockeel, C, Stoop, D, et al. Conventional Ovarian Stimulation and Single Embryo Transfer for IVF/ICSI. How Many Oocytes Do We Need to Maximize Cumulative Live Birth Rates After Utilization of All Fresh and Frozen Embryos? Hum Reprod. 2016; 31(2): 370–6.Google Scholar

Polyzos, NP, Drakopoulos, P, Parra, J, et al. Cumulative Live Birth Rates According to the Number of Oocytes Retrieved After the First Ovarian Stimulation for in Vitro Fertilization/Intracytoplasmic Sperm Injection: A Multicenter Multinational Analysis Including ~15,000 Women. Fertil Steril. 2018; 110(4): 661–70.Google Scholar

Howles, CM. Genetic Engineering of Human FSH (Gonal-F). Hum Reprod Update. 1996; 2: 172–91.CrossRef Google Scholar PubMed

Ludwig, M, Felberbaum, RE, Diedrich, K, Lunenfeld, B. Ovarian Stimulation: From Basic Science to Clinical Application. Reprod Biomed Online. 2002; 5 Suppl 1: 73–86.Google Scholar

Lunenfeld, B. Historical Perspectives in Gonadotrophin Therapy. Hum Reprod Update. 2004; 10: 453–67.Google Scholar

DiMasi, JA. Assessing Pharmaceutical Research and Development Costs. JAMA Intern Med. 2018; 178(4): 587.Google Scholar

Howles, CM. The Development of Ovarian Stimulation for IVF in in-Vitro Fertilisation: The Pioneers’ History. In: Kovacs, G, Brinsden, P. (eds.). UK: Cambridge University Press. 2018; 202–7.Google Scholar

Kushnir, VA, Barad, DH, Albertini, DF, Darmon, SK, Gleicher, N. Systematic Review of Worldwide Trends in Assisted Reproductive Technology 2004–2013. Reprod Biol Endocrinol. 2017; 15(1): 6.CrossRef Google Scholar PubMed

ESHRE conference. (2018) ICMART report. Online article. www.sciencedaily.com/releases/2018/07/180703084127.htm Google Scholar

Howles, CM, Saunders, H, Alam, V, Engrand, P. FSH Treatment Guidelines Clinical Panel. Predictive Factors and a Corresponding Treatment Algorithm for Controlled Ovarian Stimulation in Patients Treated with Recombinant Human Follicle Stimulating Hormone (Follitropin Alfa) During Assisted Reproduction Technology (ART) Procedures. An Analysis of 1378 Patients. Curr Med Res Opin. 2006.CrossRef Google Scholar

DiMasi, JA, Grabowski, HG, Hansen, RW. Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. J Health Econ. 2016; 47: 20–33.Google Scholar

Office of Health Economics. The R&D Cost of a New Medicine. Online article. www.ohe.org/publications/rd-cost-new-medicine Google Scholar

Agrawal, R, West, C, Conway, GS, Page, ML, Jacobs, HS. Pregnancy After Treatment with Three Recombinant Gonadotropins. Lancet. 1997; 349: 29–30.Google Scholar

Humaidan, P, Chin, W, Rogoff, D, et al. ESPART Study Investigators. Efficacy and Safety of Follitropin Alfa/Lutropin Alfa in ART: A Randomized Controlled Trial in Poor Ovarian Responders. Hum Reprod. 2017; 32(3): 544–55.Google Scholar

de Mora, F, Fauser, BCJM. Biosimilars to Recombinant Human FSH Medicines: Comparable Efficacy and Safety to the Original Biologic. Reprod Biomed Online. 2017;35(1): 81–6.Google Scholar

FDA Questions & Answers on Biosimilar Development. (2018). Online article. www.fda.gov/downloads/drugs/guidances/ucm444661.pdf Google Scholar

Blackstone and Fuhr Joseph. (2013). Let’s See How Biosimilars Are Developed. Online article. www.pfizerbiosimilars.com/biosimilars-development Google Scholar

Howles, CM, Loumaye, E, Giroud, D, Luyet, G. Multiple Follicular Development and Ovarian Steroidogenesis Following Subcutaneous Administration of a Highly Purified Urinary FSH Preparation in Pituitary Desensitized Women Undergoing IVF: A Multicentre European Phase III Study. Hum Reprod. 1994; 9(3): 424–30.Google Scholar

Quintans, CJ, Donaldson, MJ, Blanco, LA, Pasqualini, RS. Empty Follicle Syndrome Due to Human Errors: Its Occurrence in an in-Vitro Fertilization Programme. Hum Reprod. 1998; 13(10): 2703–5.Google Scholar

Markle, RL, King, PJ, Martin, DB. Characteristics of a Successful Human Chorionic Gonadotropin (hCG) Administration in Assisted Reproduction. Fertil Steril. 2002; 78(Suppl 1): S71–2.Google Scholar

Snaifer, E, Hugues, JN, Poncelet, C, Sifer, C, Pasquier, M, Cedrin-Durnerin, I. “Empty Follicle Syndrome” After Human Error: Pregnancy Obtained After Repeated Oocyte Retrieval in a Gonadotropin-Releasing Hormone Antagonist Cycle. Fertil Steril. 2008; 90(3): 850.e13–15.Google Scholar

Weiss, N. Gonadotrophin Products: Empowering Patients to Choose the Product That Meets Their Needs. Reprod Biomed Online. 2007; 15: 31–7.Google Scholar

Saunders, H, de la Fuente Bitaine, L, Eftekhar, C, et al. Functionality of a Novel Follitropin Alfa Pen Injector: Results from Human Factor Interactions by Patients and Nurses. Expert Opin Drug Deliv. 2018; 15(6): 549–58.Google Scholar

Zitoun, P, Parikh, J, Nijs, M, Zhang, W, Levy-Toledano, R. Tang, B. Analysis of Patient and Nurse Preferences for Self-Administered FSH Injection Devices in Select European Markets. Int J Womens Health. 2019; 11: 11–21.Google Scholar

Sedbon, E, Wainer, R, Perves, C. Quality of Life of Patients Undergoing Ovarian Stimulation with Injectable Drugs in Relation to Medical Practice in France. Reprod Biomed Online. 2006; 12, 298–303.CrossRef Google Scholar PubMed

Huisman, D, Raymakers, X, Hoomans, EH. Understanding the Burden of Ovarian Stimulation: Fertility Expert and Patient Perceptions. Reprod Biomed Online. 2009; 19 Suppl 2: 5–10.CrossRef Google Scholar PubMed

Verberg, MF, Eijkemans, MJ, Heijnen, EM, et al. Why Do Couples Drop-out from IVF Treatment? A Prospective Cohort Study. Hum Reprod. 2008; 23(9): 2050–5.Google Scholar

Brod, M, Verhaak, CM, Wiebinga, CJ, Gerris, J, Hoomans, EH. Improving Clinical Understanding of the Effect of Ovarian Stimulation on Women’s Lives. Reprod Biomed Online. 2009; 18(3): 391–400.Google Scholar

Fares, FA, Suganuma, N, Nishimori, K, et al. Design of a Long-Acting Follitropin Agonist by Fusing the C-Terminal Sequence of the Chorionic Gonadotropin Beta Subunit to the Follitropin Beta Subunit. Proc Natl Acad Sci USA. 1992; 89: 4304–8.CrossRef Google Scholar

Beckers, NG, Macklon, NS, Devroey, P, Platteau, P, Boerrigter, PJ, Fauser, BC. First Live Birth After Ovarian Stimulation Using a Chimeric Long-Acting Human Recombinant Follicle-Stimulating Hormone (FSH) Agonist (recFSH-CTP) For in Vitro Fertilization. Fertil Steril. 2003; 79(3): 621–3.Google Scholar

Merck & Co Annual Report for the Fiscal Year Ended Dec 31 2015 (filed with the Securities and Exchange Commission in February 2016). Online report. www.sec.gov/Archives/edgar/data/310158/000031015816000063/mrk1231201510k.htm Google Scholar

le Cotonnec, JY, Porchet, HC, Beltrami, V, Khan, A, Toon, S, Rowland, M. Clinical Pharmacology of Recombinant Human Follicle-Stimulating Hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. Fertil Steril. 1994; 61(4): 669–78.Google Scholar

Scholtes, MC, Schnittert, B, van Hoogstraten, D, Verhoeven, HC, Zrener, A, Warne, DW. A Comparison of 3-Day and Daily Follicle-Stimulating Hormone Injections on Stimulation Days 1–6 in Women Undergoing Controlled Ovarian Hyperstimulation. Fertil Steril. 2004; 81: 996–1001.Google Scholar

Sharma, V, Williams, J, Collins, W, Riddle, A, Mason, B, Whitehead, M. A Comparison of Treatments with Exogenous FSH to Promote Folliculogenesis in Patients with Quiescent Ovaries Due to the Continued Administration of an LH-RH Agonist. Hum Reprod. 1987; 2: 553–6.Google Scholar

ClinicalTrials.gov Identifier: NCT03019575. Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH). Online article. https://clinicaltrials.gov/ct2/show/NCT03019575 Google Scholar

Howles, CM, Tanaka, T, Matsuda, T. Management of Male Hypogonadotrophic Hypogonadism. Endocr J. 2007; 54(2): 177–90.Google Scholar

Olsson, H, Sandstrom, R, Grundemar, L. Different Pharmacokinetic and Pharmacodynamic Properties of Recombinant Follicle-Stimulating Hormone (rFSH) Derived from a Human Cell Line Compared with rFSH from a Non-Human Cell Line. J Clin Pharmacol. 2014; 54: 1299–307.Google Scholar

Arce, JC, Andersen, AN, Fernández-Sánchez, M, et al. Ovarian Response to Recombinant Human Follicle-Stimulating Hormone: A Randomized, Antimüllerian Hormone-Stratified, Dose-Response Trial in Women Undergoing in Vitro Fertilization/Intracytoplasmic Sperm Injection. Fertil Steril. 2014; 102: 1633–40.CrossRef Google Scholar PubMed

Haute Autorité de Santé. Online article. https://www.has-sante.fr/upload/docs/application/pdf/2017-09/rekovelle_summary_ct15912.pdf Google Scholar

Abd-Elaziz, K, Duijkers, I, Stöckl, L, et al. A New Fully Human Recombinant FSH (Follitropin Epsilon): Two Phase I Randomized Placebo and Comparator-Controlled Pharmacokinetic and Pharmacodynamic Trials. Hum Reprod. 2017; 7: 1–9.Google Scholar

Millar, RP, Zhu, YF, Chen, C, Struthers, RS. Progress Towards the Development of Non-Peptide Orally-Active Gonadotropin-Releasing Hormone (GnRH) Antagonists: Therapeutic Implications. Br Med Bull. 2000; 56(3): 761–72.Google Scholar

ASRM fact sheet Endometriosis. Online article. www.reproductivefacts.org/news-and-publications/patient-fact-sheets-and-booklets/documents/fact-sheets-and-info-booklets/endometriosis-booklet Google Scholar

Clarivate Analytics. (2018). Sales Forecasts Rise for AbbVie’s Elagolix Following Expected Approval in Endometriosis. Online article. https://clarivate.com/blog/life-sciences-connect/sales-forecasts-rise-for-abbvies-elagolix-following-expected-approval-in-endometriosis/Google Scholar

Vercellini, P, Viganò, P, Barbara, G, Buggio, L, Somigliana, E. “Luigi Mangiagalli” Endometriosis Study Group. Elagolix for Endometriosis: All That Glitters Is Not Gold. Hum Reprod. 2018.Google Scholar

Paulson, RJ. At Last, an Orally Active Gonadotropin-Releasing Hormone Antagonist. Fertil Steril. 2019; 111(1): 30–1.Google Scholar

Arey, BJ, Deecher, DC, Shen, ES, et al. Identification and Characterization of a Selective, Nonpeptide Follicle-Stimulating Hormone Receptor Antagonist. Endocrinology. 2002; 143.Google Scholar

Guo, T, Adang, AE, Dolle, RE, et al. Small Molecule Biaryl FSH Receptor Agonists. Part 1: Lead Discovery Via Encoded Combinatorial Synthesis. Bioorg Med Chem Lett. 2004; 14(7): 1713–16.Google Scholar

Maclean, D, Holden, F, Davis, AM, et al. Agonists of the Follicle Stimulating Hormone Receptor from an Encoded Thiazolidinone Library. J Comb Chem. 2004; 6.Google Scholar

Howles, CM, Arkinstall, S. Developing new therapeutics for ART: recombinant DNA technology and beyond. In: Textbook of Assisted Reproductive Techniques: Laboratory and Clinical Perspectives Edition: 1. Gardner, DK, Weissman, A, Howles, CM, Shoham, Z (eds.). Taylor & Francis.Google Scholar

Palmer, SS, McKenna, S, Arkinstall, S. Discovery of New Molecules for Future Treatment of Infertility. Reprod Biomed Online. 2005; 10 Suppl 3: 45–54.Google Scholar

Nataraja, SG, Yu, HN, Palmer, SS. Discovery and Development of Small Molecule Allosteric Modulators of Glycoprotein Hormone Receptors. Front Endocrinol (Lausanne). 2015; 6: 142.Google Scholar

van de Lagemaat, R, Timmers, CM, Kelder, J, van Koppen, C, Mosselman, S, Hanssen, RG. Induction of Ovulation by a Potent, Orally Active, Low Molecular Weight Agonist (Org 43553) of the Luteinizing Hormone Receptor. Hum Reprod. 2009; 24(3): 640–8.Google Scholar

Mannaerts, B. Novel FSH and LH agonists. From anovulation to assisted reproduction. Proceedings of the Fourth World Congress on Ovulation. In: Filicori, M (ed.) 2004; 157–72.Google Scholar

Howles, CM, Macnamee, MC, Edwards, RG. Follicular Development and Early Luteal Function of Conception and Non-Conceptional Cycles After Human in-Vitro Fertilization: Endocrine Correlates. Hum Reprod. 1987; 2(1): 17–21.Google Scholar

Jones, HW, Jr., Jones, GS, Andrews, MC, et al. The Program for in Vitro Fertilization at Norfolk. Fertil Steril 1982; 38: 14–21.Google Scholar

van der Linden, M, Buckingham, K, Farquhar, C, Kremer, JA, Metwally, M. Luteal Phase Support for Assisted Reproduction Cycles. Cochrane Database Syst Rev. 2015; CD009154.Google Scholar

Weissman, A. A Survey on Luteal-Phase Support. (2018). ISARG Conference, Tel Aviv, Israel. Online article. http://cme-utilities.com/mailshotcme/SARG/Presentations/1200_Weissman_B_Tue.pdf Google Scholar

Humaidan, P, Bredkjaer, HE, Bungum, L, et al. GnRH Agonist (Buserelin) or hCG for Ovulation Induction in GnRH Antagonist IVF/ICSI Cycles: A Prospective Randomized Study. Hum Reprod. 2005; 20: 1213–20.Google Scholar

Tournaye, H, Sukhikh, GT, Kahler, E, Griesinger, G. A Phase III Randomized Controlled Trial Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone Versus Micronized Vaginal Progesterone for Luteal Support in in Vitro Fertilization. Hum Reprod. 2017; 32(10): 2152.Google Scholar

Griesinger, G, Blockeel, C, Sukhikh, GT, et al. Oral Dydrogesterone Versus Intravaginal Micronized Progesterone Gel for Luteal Phase Support in IVF: A Randomized Clinical Trial. Hum Reprod. 2018; 33(12): 2212–21.Google Scholar

Griesinger, G, Blockeel, C, Kahler, E, Pexman-Fieth, C. Use of Oral Dydrogesterone for Luteal Phase Support in Fresh IVF Cycles Is Associated with an Increase in Live Birth Rate: An Integrated Individual Patient Data Analysis of the Lotus Phase III Trial Program. Fertil Steril. 2018; 110(4): e90.Google Scholar

Labarta, E, Mariani, G, Holtmann, N, Celada, P, Remohí, J, Bosch, E. Low Serum Progesterone on the Day of Embryo Transfer Is Associated with a Diminished Ongoing Pregnancy Rate in Oocyte Donation Cycles After Artificial Endometrial Preparation: A Prospective Study. Hum Reprod. 2017; 32(12): 2437–42.Google Scholar

Alsbjerg, B, Thomsen, L, Elbaek, HO, et al. Progesterone Levels on Pregnancy Test Day After Hormone Replacement Therapy-Cryopreserved Embryo Transfer Cycles and Related Reproductive Outcomes. Reprod Biomed Online. 2018; 37(5): 641–7.Google Scholar

Alsbjerg, B, Polyzos, NP, Elbaek, HO, Povlsen, BB, Andersen, CY, Humaidan, P. Increasing Vaginal Progesterone Gel Supplementation After Frozen-Thawed Embryo Transfer Significantly Increases the Delivery Rate. Reprod Biomed Online. 2013; 26(2): 133–7.Google Scholar

Griesinger, G, Blockeel, C, Tournaye, H. Oral Dydrogesterone for Luteal Phase Support in Fresh in Vitro Fertilization Cycles: A New Standard? Fertil Steril. 2018; 109(5): 756–62.Google Scholar

Visnova, H, Tournaye, H, Humberstone, A, Terrill, P, Macgregor, L, Loumaye, E. A Placebo-Controlled, Randomized, Double-Blind, Phase 3 Study Assessing Ongoing Pregnancy Rates After Single Oral Administration of a Novel Oxytocin Receptor Antagonist, Nolasiban, Prior to Single Embryo Transfer. Fertil Steril. 2018; 110(4): e45.Google Scholar

Howles, CM. Recombinant Gonadotrophins in Reproductive Medicine: The Gold Standard of Today. Reprod Biomed Online. 2006; 12: 11–13.Google Scholar